Mariagrazia Del Buono

TL;DR: In this article, a randomized controlled trial was performed to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis.

TL;DR: In a small randomized controlled trial, a 12-month course of enoxaparin was safe and effective in preventing PVT in patients with cirrhosis and a Child-Pugh score of 7-10 and to improve survival.

TL;DR: The presence of variant liver ER transcripts in the tumor was the strongest negative predictor of survival in inoperable hepatocellular carcinoma and their presence was associated with spontaneous survival significantly worse than in patients with wild‐type estrogen receptors.

TL;DR: The hepatic five-gene signature was able to predict HCC growth in individual patient and the consequent risk of death and implies a role of this molecular tool in the future therapeutic management of patients with HCC.

TL;DR: It is indicated that DAA‐mediated increase of VEGF favors HCC recurrence/occurrence in susceptible patients, that is, those with more severe fibrosis and splanchnic collateralization, who already have abnormal activation in liver tissues of neo‐angiogenetic pathways, as shown by increased ANGPT2.